Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J-Y Reginster

Showing results (11-20 of 394) with videos related to

Pageof 40
Sort By:
Clinical Rheumatology|September 1, 1995
The role of bisphosphonates in the prevention and treatment of osteoporosisJ Y Reginster
Bone|January 1, 1992
Management of high turnover osteoporosis with calcitoninJ Y Reginster
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 1, 1993
Calcitonins: newer routes of deliveryJ Y Reginster
Pathologie-Biologie|January 1, 1997
[Calcitonin and bone aging]J Y Reginster
Bone and Mineral|December 1, 1993
Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosisJ Y Reginster
The American Journal of Medicine|November 30, 1993
Calcitonin for prevention and treatment of osteoporosisJ Y Reginster
Rheumatology (Oxford, England)|August 14, 2002
The prevalence and burden of arthritisJ Y Reginster
Revue Medicale De Liege|January 26, 2008
[Strontium ranlelate (Protelos)]J Y Reginster
Current Drug Metabolism|November 1, 2006
Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosisJ-Y Reginster, R Gieschke
Revue Medicale De Liege|February 5, 2003
[Quality of life assessment in clinical trials: a holistic approach to health]O Ethgen, J Y Reginster
Pageof 40

Showing results (11-20 of 394) with videos related to

Sort By:
Pageof 40
Clinical Rheumatology|September 1, 1995
The role of bisphosphonates in the prevention and treatment of osteoporosisJ Y Reginster
Bone|January 1, 1992
Management of high turnover osteoporosis with calcitoninJ Y Reginster
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 1, 1993
Calcitonins: newer routes of deliveryJ Y Reginster
Pathologie-Biologie|January 1, 1997
[Calcitonin and bone aging]J Y Reginster
Bone and Mineral|December 1, 1993
Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosisJ Y Reginster
The American Journal of Medicine|November 30, 1993
Calcitonin for prevention and treatment of osteoporosisJ Y Reginster
Rheumatology (Oxford, England)|August 14, 2002
The prevalence and burden of arthritisJ Y Reginster
Revue Medicale De Liege|January 26, 2008
[Strontium ranlelate (Protelos)]J Y Reginster
Current Drug Metabolism|November 1, 2006
Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosisJ-Y Reginster, R Gieschke
Revue Medicale De Liege|February 5, 2003
[Quality of life assessment in clinical trials: a holistic approach to health]O Ethgen, J Y Reginster
Pageof 40